Eris Lifesciences has received approval for the issuance of Non-convertible Debentures (NCDs) for an amount aggregating up to Rs 1250 crore in one or multiple series through Private Placement. The Board of Directors of the company, in their meeting held on May 21, 2024, duly approved the same.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
